In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Impact of multivessel coronary artery disease on long term prognosis in patients with ST-elevation myocardial infarction

Session Poster Session 1

Speaker Assistant Professor Lidija Savic

Congress : Acute Cardiovascular Care 2019

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : ST-Elevation Myocardial Infarction (STEMI)
  • Session type : Poster Session
  • FP Number : P213

Authors : L Savic (Belgrade,RS), I Mrdovic (Belgrade,RS), M Asanin (Belgrade,RS), G Krljanac (Belgrade,RS), R Lasica (Belgrade,RS), D Rajic (Belgrade,RS), B Kastel (Belgrade,RS)

L Savic1 , I Mrdovic2 , M Asanin2 , G Krljanac2 , R Lasica2 , D Rajic2 , B Kastel2 , 1Clinical Center of Serbia, Institute for Cardiovascular Disease - Belgrade - Serbia , 2Clinical Center of Serbia, Institute for Cardiovascular Disease, Emergency Hospital - Belgrade - Serbia ,


Background/aim: A significant proportion of patients with ST elevation myocardial infarction (STEMI) has multivessel coronary artery disease (MVD) and they are at high risk for reccurent cardiac events. The aim of the present study is to analyse the impact of MVD on 6-year cardiovascular mortallity in STEMI patients treated with primary percutaneous coronary intervention (pPCI).

Method: This study included 2700 consecutive STEMI patients hospitalized in Clinical centre of Serbia, Coronary Care Unit, between november 2005 and june 2011. Patients were divided in two groups: MVD and single-vessel disease. MVD disease was defined as diameter stenosis greater than 50% by visual assessment in more than one major coronary artery. Primary PCI was limited to the infarct related artery (IRA). Echocardiographic examination was performed before hospital discharge. Cardiovascular mortality was defined as any death from cardiovascular reason (myocardial re-infarction, sudden death or heart failure). Patients presenting with cardiogenic shock were excluded.

Results: Among 2700 analyzed patients 1152 (44.3%) had single-vessel disease and 1450 (55.7%) had MVD. Among patients with MVD, 52.9% had two-vessel disease and 47.1% had three-vessel disease. As compared with patients with single-vessel disease, patients with MVD were older and presented more often with heart failure; they were more likely to heave previous coronary disease, diabetes, hypertension and chronic kidney disease; post-procedural flow TIMI <3 and was more frequently observed in patients with MVD than in patients with single-vessel disease (6.5% vs 3.3%, respectively, p<0.001). Patients with MVD had lower EF than patients with single-vessel disease 47%(IQR 40%-55%) vs 50% (IQR 49%-55%), p<0.001. Revascularization of non-IRA lesions was performed in the first few months after pPCI (median 1.5 month, IQR 1-3 months) in 1303 (89.7%) patients and in 147 (10.3%) patients with MVD revascularization was performed later during follow-up; coronary artery bypass grafting was performed in 278 (19.2%) patients and PCI (with stent implantation) in 1171 (80.8%) patients. Six year cardiovascular mortality was significantly higher in patients with MVD than in patients with single-vessel disease (10.4% vs 4.6%, p<0.001) as presented in Figure 1. In multivariate Cox regression analysis MVD remained an independent predictor for 6-year cardiovascular mortality (HR 1.55, 95%CI 1.11-2.06, p=0.041). Other independent predictors were heart failure at admission (HR 4.23, 95%CI 3.31-5.36, p<0.001), postprocedural flow TIMI<3 (HR 3.23, 95%CI 2.35-4.78, p<0.001), chronic kidney disease (HR 1.75, 95%CI 1.29-2.49, p=0,024) and older age (HR 1.03, 95%CI 1.02-1.04, p<0.001).

Conclusion: In STEMI patients treated with pPCI the presence of MVD remains independently associated with high 6-year cardiovascular mortality despite relatively early revascularization of non-IRA lesions.

The free consultation period for this content is over.

It is now only available year-round to ACCA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are